KLF4 (KLF transcription factor 4; HGNC:6348, NCBI Gene 9314) is the gene on chromosome 9q31.2 encoding Kruppel-like factor 4 — the zinc-finger transcription factor of epithelial differentiation and cell-cycle arrest (p21 induction, a "gut-enriched" KLF) that became one of the four Yamanaka factors: with OCT4, SOX2, and c-MYC it reprograms somatic cells to induced pluripotency.
Approved Symbol
KLF4 (HGNC:6348)
Chromosomal Locus
9q31.2
Encoded Product
KLF4 — a 55-kDa zinc-finger transcription factor (513 aa)
Primary Pathway
Differentiation/p21 arrest program; with OCT4/SOX2/MYC → induced pluripotency
Clinical / Therapeutic Role
The iPS-cell reprogramming quartet; differentiation and barrier biology
Gene Structure & Expression
Genomic organization: Five exons; three C2H2 zinc fingers at the C-terminus (DNA binding) and the N-terminal activation/repression domains that recruit p300/CBP or HDACs contextually.
Expression: Gut and skin epithelium (differentiation), macrophages (inflammation-activated), and senescent cells — the same factor stabilising pluripotency in reprogramming while driving differentiation in tissues, depending on its partners.
Molecular Function & Pathways
Reprogramming: In the Yamanaka combination KLF4 maintains the epithelial and self-renewal program — the 2006 discovery (with the 2012 Nobel) that made pluripotency inducible; alone, KLF4 drives p21-mediated arrest and differentiation.
Barrier and inflammation: Gut-epithelial KLF4 maintains the differentiation of goblet and absorptive lineages; inflammatory signaling (via NF-κB cross-talk) modulates it in barrier disease.
Clinical & Therapeutic Significance
Stem-cell biology: iPS reprogramming's workhorse — KLF4's inclusion in the quartet making it one of the most-cited genes in regenerative medicine, its dual function (arrest and pluripotency) reconciled by the partners it keeps in each context: with OCT4/SOX2 it holds pluripotency; alone in the gut it finishes differentiation — the same protein read two ways by the cell. GWAS tie KLF4-binding variation to inflammatory-bowel-disease risk, connecting its barrier role to human genetics.
Cancer: Context-dependent — tumor-suppressive (p21, differentiation) in some cancers, amplified or oncogenic in others; KLF4 polymorphisms in inflammatory-bowel-disease susceptibility.